Uric acid promotes the proliferation and migration of prostate cancer cell through down-regulating the expression of lncRNA MIR22HG#br#
LI Ansu1, SHAO Shihe1, WANG Xiuping1, ZHU Huazi1, HU Jianpeng2
(1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of Urology Surgery, Affliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002, China)
Abstract:[Abstract]Objective: To investigate whether uric acid (UA) regulates the proliferation and migration of prostate cancer cells through lncRNA MIR22HG. Methods: Prostate cancer DU145 cells were divided into control group and UA (400 μmol/L) treatment group, transfected with siMIR22HG or siNC group, and transfected with pcDNAMIR22HG or pcDNA group, and UA+pcDNA-MIR22HG or UA+pcDNA group. The expression of MIR22HG in DU145 cells was detected by qRT-PCR, the cell proliferation ability was detected by CCK-8, the expression of cell cycle related factors (Cyclin D1, CDK4 and P21) was detected by Western blotting, and the cell migration ability was measured by Transwell. Results: Compared with the control group, after being treated with 400 μmol/L uric acid, the expression of MIR22HG in DU145 cells decreased significantly (P<0.01), the viability and migration ability of prostate cancer DU145 cells increased significantly (P<0.01), the expression levels of Cyclin D1 and CDK4 protein increased significantly (P<0.01), and the expression level of P21 protein decreased significantly (P<0.01). Compared with the corresponding control group, downregulation of MIR22HG could significantly promote the proliferation and migration of prostate cancer DU145 cells (P<0.01), while upregulation of MIR22HG could inhibit their proliferation and migration (P<0.01). At the same time, overexpression of MIR22HG could reverse the promoting effect of uric acid on the proliferation and migration of DU145 cells (P<0.01). Conclusion: Uric acid can promote the proliferation and migration of prostate cancer cells, which may be attributed to the down regulation of MIR22HG expression.
李安苏, 邵世和, 王秀平,等.. 尿酸通过下调lncRNA MIR22HG的表达促进前列腺癌细胞增殖及迁移[J]. 江苏大学学报:医学版, 2022, 32(05): 385-390.
LI Ansu1, SHAO Shihe1, WANG Xiuping1, ZHU Huazi1, HU Jianpeng2. Uric acid promotes the proliferation and migration of prostate cancer cell through down-regulating the expression of lncRNA MIR22HG#br#. Journal of Jiangsu University(Medicine Edition), 2022, 32(05): 385-390.
[1]Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[2]Sandhu S, Moore CM, Chiong E, et al. Prostate cancer[J]. Lancet, 2021, 398(10305): 1075-1090.
[3]Siroosbakht S, Rezakhaniha S, Namdari F, et al. Is there relationship between serum uric acid levels and lower urinary tract symptoms, prostate volume, and PSA in men without cancer? A prospective populationbased study[J]. Andrologia, 2021, 53(10): e14200.
[4]Fini MA, Elias A, Johnson RJ, et al. Contribution of uric acid to cancer risk, recurrence, and mortality[J]. Clin Transl Med, 2012, 1(1): 1-15.
[5]Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidantand radicalcaused aging and cancer: a hypothesis[J]. Proc Natl Acad Sci U S A, 1981, 78(11): 6858-6862.
[6]Chen MM, Meng LH. The double faced role of xanthine oxidoreductase in cancer[J]. Acta Pharmacol Sin, 2022, 43(7): 1623-1632.
[7]Ulitsky I, Bartel DP. LincRNAs: genomics, evolution, and mechanisms[J]. Cell, 2013, 154(1): 26-46.
[8]周新童,任天宇,党胜春. 长链非编码RNA AL139147.1在胃癌中的表达及对MKN45胃癌细胞生长的影响[J]. 江苏大学学报(医学版), 2021, 31(1): 51-55.
[9]张鹤腾,唐银炳,谢文杰,等. 长链非编码RNA SPATA3AS1在胃癌中的表达及意义[J]. 江苏大学学报(医学版), 2021, 31(6): 489-495.
[10]Statello L, Guo C, Chen L, et al. Gene regulation by long noncoding RNAs and its biological functions[J]. Nat Rev Mol Cel Bio, 2021, 22(2): 96-118.
[11]Shen H, Weng XD, Yang D, et al. Long noncoding RNA MIR22HG is downregulated in prostate cancer[J]. Math Biosci Eng, 2019, 17(2): 1776-1786.
[12]Sangkop F,Singh G, Rodrigues E, et al. Uric acid: a modulator of prostate cells and activin sensitivity[J]. Mol Cel Biochem, 2016, 414(1-2): 187-199.
[13]Wu L,Yang W, Zhang Y, et al. Elevated serum uric acid is associated with poor survival in advanced HCC patients and febuxostat improves prognosis in HCC rats[J]. Front Pharmacol, 2021, 12: 778890.
[14]Stotz M, Szkandera J, Seidel J, et al. Evaluation of uric acid as a prognostic bloodbased marker in a large cohort of pancreatic cancer patients[J]. PLoS One, 2014, 9(8): e104730.
[15]Dhankhar R, Dahiya K, Sharma TK, et al. Diagnostic significance of adenosine deaminase, uric acid and Creactive protein levels in patients of head and neck carcinoma[J]. Clin Lab, 2011, 57(9-10): 795-798.
[16]Kolonel LN, Yoshizawa C, Nomura AM, et al. Relationship of serum uric acid to cancer occurrence in a prospective male cohort[J]. Cancer Epidemiol Biomarkers Prev, 1994, 3(3): 225-228.
[17]Hammarsten J, Damber JE, Peeker R, et al. A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer[J]. Cancer Epidemiol, 2010, 34(5): 574-579.
[18]Wang A, Barber JR, Tin A, et al. Serum urate, genetic variation, and prostate cancer risk: Atherosclerosis Risk in Communities(ARIC) Study[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(7): 1259-1261.
[19]Benli E, Cirakoglu A, Ayyldz SN, et al. Comparison of serum uric acid levels between prostate cancer patients and a control group[J]. Cent European J Urol, 2018, 71(2): 242-247.
[20]Slack FJ, Chinnaiyan AM. The role of noncoding RNAs in oncology[J]. Cell, 2019, 179(5): 1033-1055.
[21]Li P, Xu H, Yang L, et al. E2F transcription factor 2activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoidinduced protein kinase 1[J]. Cell Death Dis, 2022, 13(1): 77.
[22]Zhang D, Zou X, Cao C, et al. Identification and functional characterization of long noncoding RNA MIR22HG as a tumor suppressor for hepatocellular carcinoma[J]. Theranostics, 2018, 8(14): 3751-3765.
[23]Deng X, Ye D, Hua K, et al. MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor[J]. Cell Death Dis, 2021, 12(9): 810.
[24]Xu J, Shao T, Song M, et al. MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer[J]. Mol Cancer, 2020, 19(1): 51.